We break down why resistant hypertension can be so hard to control, and how aldosterone drives sodium retention, vascular stiffening, and persistent high blood pressure. The episode also examines the BaxHTN trial of baxdrostat, including its blood pressure benefits, the risk of hyperkalemia, and what still needs to be proven about long-term outcomes.

Show Notes

• Efficacy and Safety of Baxdrostat in Uncontrolled and ...: https://www.nejm.org/doi/abs/10.1056/NEJMoa2507109

This episode breaks down how finerenone is changing care for patients with preserved or mildly reduced ejection fraction heart failure, moving beyond the limitations of spironolactone and other steroidal MRAs. The hosts review the FINEARTS HF trial results, including fewer worsening heart failure events, the lack of a clear mortality benefit, and the real-world need to monitor potassium and kidney function closely.

Show Notes

• Finerenone in Heart Failure with Mildly Reduced or ...: https://www.nejm.org/doi/abs/10.1056/NEJMoa2407107

An in-depth look at a new once-weekly HIV treatment strategy that matched daily therapy in a head-to-head trial, with discussion of adherence fatigue, viral suppression, and the importance of diverse clinical data.

The episode also explores the pharmacology behind islatravir and lenacapavir, plus the safety concerns that nearly derailed islatravir before researchers found a lower-dose path forward.

A deep dive into why suspected pulmonary embolism is so hard to manage in patients with active cancer, from the risks of routine CT scanning to the promise of the YEARS diagnostic pathway. The episode also unpacks the Hydra trial and the Bayesian logic behind why a rule-out strategy that works in the general population may still leave a meaningful residual risk in oncology patients.

A deep dive into why a promising meningitis B vaccine appeared to reduce gonorrhea in observational studies, only for a randomized trial to show the protection vanished. The hosts unpack cross-protection, mucosal immunity, and the confounding factors that can make a public health breakthrough look far more real than it is.

An in-depth look at how researchers finally tested shunt surgery for idiopathic normal pressure hydrocephalus without sham operations, using a magnetic valve to compare active drainage against placebo. The findings reveal a major boost in walking and balance, but little short-term benefit for cognition or bladder symptoms, along with the risks of overdrainage.

This episode explores the paradox of ischemic reperfusion injury in acute STEMI and the theory behind pre-reperfusion ventricular unloading with Impella CP. The hosts break down the STEMI DTU trial, showing why a deliberate 30-minute delay failed to reduce infarct size and dramatically increased bleeding and vascular complications.

A look at the 2024 paternal valproate warning, the biology behind the 90-day spermatogenesis window, and how early registry signals sparked major counseling dilemmas for men with epilepsy or bipolar disorder.

The episode then unpacks a large 2026 study showing the apparent risk largely disappeared after controlling for confounding by indication, offering reassurance for clinical decision-making.

This episode breaks down the CHAMPION-AF trial, where left atrial appendage closure was tested against DOACs in typical atrial fibrillation patients who were eligible for either treatment. The hosts explore why the device lowered long-term bleeding but came with procedural tradeoffs and a slightly higher numerical stroke rate.

Show Notes

• CHAMPION-AF: Left Atrial Appendage Closure vs. ...: https://www.acc.org/latest-in-cardiology/articles/2026/03/25/21/27/sat-930am-championaf-acc-2026

We break down how PCSK9 inhibition with evolocumab can sharply lower LDL and reduce first-time cardiovascular events in high-risk patients who have never had a heart attack or stroke. The episode also weighs the real-world tradeoffs: absolute risk reduction, NNT, cost, and the limits of applying trial results to more diverse populations.